News

In this segment, Negroski comments on the realism behind wearing off effect of treatments, specifically ocrelizumab, and how clinicians may work around some of these issues.

Additional data of a phase 2 study presented at the 2024 SLEEP Annual Meeting demonstrated that pitolisant significantly improved in secondary end points among patients with myotonic dystrophy type 1.

Negroski discussed some of the takeaways from an analysis of patients with stable MS who chose to switch from natalizumab to other, more moderate-efficacy oral disease-modifying therapies.

Clinically meaningful reductions in seizures through fenfluramine is likely to contribute to nonseizure benefits such as improvement in comorbidities, decreased use of other antiseizure medications, and reduction in premature death.

Istradefylline led to significant reductions in tremor and motor symptoms in patients with Parkinson disease over 24 weeks.

Sleeping Around the Podcast × NeurologyLive brings you a clinical overview of the importance of calcitonin gene-related peptide protein in sleep, and some previously published data to support the role it plays.

Findings revealed that 27% of patients responded to the treatment of continuous subcutaneous apomorphine infusion and sustained efficacy overtime in patients with Parkinson disease.

The movement disorder specialist at Texas Movement Disorder Specialists talked about a comprehensive panel discussion that highlighted the evolution of Parkinson disease treatment. [WATCH TIME: 4 minutes]

In honor of Insomnia Awareness Night, the president of the American Academy of Sleep Medicine board of directors talked about increasing awareness of the sleep disorder for the clinical and patient community. [WATCH TIME: 6 minutes]

Bezisterim has shown potential in improving non-motor symptoms like fatigue and sleep issues, with promising results from previous studies.

Modified Functional Status Questionnaire, an assessment of activities of daily living, includes several different notable domains, including quality of interaction, social activity, and psychological function.

In the CRL, the agency cited observations identified during inspection of a third-party manufacturer listed in the NDA. If approved, ABBV-951 would be the first subcutaneous delivery option of carbidopa/levodopa.

The director of the Memory Disorders Program at Georgetown University talked about newly approved anti-amyloid antibodies that show significant promise in slowing Alzheimer disease progression. [WATCH TIME: 5 minutes]

Although the data used predated 2019, istradefylline was associated with a statistically significant lower odds of the overall incidence of treatment-emergent adverse events than other adjunctive therapies for Parkinson disease.

StrivePD and Apple Watch continuously track motor symptoms, aiding neurologists in adjusting treatments for better patient outcomes.

In a large-scale analysis. 70% of patients with essential tremor and 70% of undiagnosed patients reported dissatisfaction with the therapeutic options available to treat their condition.

The associate professor of neurology at Georgetown University Medical Center talked about disease-modifying therapies for movement disorder-related dementia that aim to address the underlying mechanisms of the disease. [WATCH TIME: 5 minutes]

The executive director of the Association of Movement Disorder Advanced Practice Providers talked about the need for improved communication and trust of the patient-provider relationship in the field of movement disorders. [WATCH TIME: 3 minutes]

The assistant clinical professor of medicine at Medstar Georgetown University Hospital talked about her presentation at ATMRD where she covered various advanced therapies for managing Parkinson disease and essential tremor. [WATCH TIME: 5 minutes]

Pitolisant is the first and only drug in the class of antagonist/reverse agonists of the histamine H3 receptor for the treatment of patients with narcolepsy.

Here's some of what is coming soon to NeurologyLive® this week.

Approximately 83% of patients reported that they did not disclose to their provider that they experienced symptoms or had concerns about living with a movement disorder.

The director of movement disorders at the Banner Sun Health Research Institute talked about that although synuclein biomarkers have shown high sensitivity in identifying Parkinson disease, further studies are needed to address their limitations. [WATCH TIME: 3 minutes]

In recent analysis indicated that initiating apomorphine hydrochloride injection without antiemetic premedication was well-tolerated among patients with Parkinson disease.

Neurology News Network. for the week ending June 22, 2024. [WATCH TIME: 4 minutes]

An open-label phase 2b trial assessing ND0612 showed that the rate of treatment responders increased over a 12-month period among patients with Parkinson disease who experienced motor fluctuation.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on Alzheimer disease/dementia.

Patients treated with at least 12.5 mg/day of oral prednisone for at least 3 months had an 88% reduction in the risk of relapse compared with those who did not receive this regimen.